5EQ, BOX Docket No.

TRANSMITTAL LETTER (General Ratent Pending)			Docket No. A003-CIP	
In Re Application Of: Browning, J. et al	MAY 0 8 2000 00			
Serial No. 09/245,198	Filing Date February 5, 1999	Examiner Kerr, J.	Group Art Unit 1633	
Title: A TUMOR NECROSIS FACTOR RELATED LIGAND			RECEIVED MAY 1 5 2000 TECH CENTER 1800/2900	
TO THE ASSISTANT COMMISSIONER FOR PATENTS:				
Transmitted herewith is: Transmittal letter (induplicate); Certificate of Mailing by Express Mail; Sequence Listing diskette; Paper Sequence Listing; Copy of Notice to Comply; Statement Regarding Content of Disk; Postcard RECEVED				
•	iny additional fee required.	on 8 May 2000 first class mail under 37 C Assistant Commissioner 20281.	nent and fee is being deposited with the U.S. Postal Service as c.F.R. 1.8 and is addressed to the for Patents, Washington, D.C.	

Laura M. McGuire

Typed or Printed Name of Person Mailing Correspondence

cc:

Docket: A003 US

IN THE UNITED STATES RECEIVING OFFICE



application of:

BIOGEN ET AL.

U.S. Serial No.:

09/245,198

U.S. Filing date:

5 February 1999

For:

A TUMOR NECROSIS FACTOR RELATED LIGAND

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence, together with all items referred to herein, is being deposited with the United States Post Office as Express Mail Label No. EL543620742US in an Express Mail Evelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on the date shown below.

Date

Laura M. McGuire

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith is a diskette containing a machine readable copy of the Sequence Listing set forth on pages 1 to 7 of the Paper Sequence listing for the abovereferenced Patent Application as filed herewith.

The content of the Sequence Listing diskette submitted herewith are the same as the contents of the paper form of the Sequence Listing submitted herewith.

If there are any questions, please contact the undersigned by telephone.

Respectfully submitted,

Date: 5/8/00

Niki D. Cox

Reg. No. 42,446 BIOGEN, INC.

617-679-2079 (direct)

Application No.:09/245,198

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: the topology of the sequence was not reported.
Applicant Must Provide:
An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entinto the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Dulco Intermedation, cell (700) 200, 4040

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE